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Background: Visceral obesity is often accompanied by non-alcoholic fatty liver disease (NAFLD). Activation of
NACHT, LRR and PYD domains-containing proteins (NALPs) may contribute to the release of pro-inflammatory
cytokines by adipose and the obesity-associated progression of NAFLD to non-alcoholic steatohepatitis (NASH).
Methods: We analyzed visceral adipose expression of various NALPs and its downstream effectors caspase-1, ASC
(Apoptosis-associated speck-like protein containing a CARD), IL-18 (Interleukin-18) and IL-1β (Interleukin- 1Beta) in
obese subjects (BMI ≥ 35) with biopsy proven NAFLD.
Results: In adipose samples collected from NASH and pericellular fibrosis patients cohorts, expression levels of
NALPs and IL-1β were lower than that in non-NASH patients. In portal fibrosis, the levels of mRNA encoding
anti-inflammatory NALP6 were upregulated. The expression levels of all NALPs were significantly co-correlated.
Circulating IL-18 levels were associated with increased liver injury markers AST and ALT and portal fibrosis.
Conclusion: Our observations point at a possible shift in inflammation and fibrotic response from adipose tissue to
liver and a possible negative feedback regulation of tissue inflammation that may instigate NAFLD severity.
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The prevalence of obesity in United States has remained
unabated over the past 10 years with ~35% prevalence
among adults [1]. A pro-inflammatory state (also referred
to as low-grade chronic inflammation/meta-inflammation/
sterile inflammation) associated with visceral obesity, has
been also shown to be strongly correlated with the devel-
opment of non-alcoholic fatty liver disease (NAFLD) [2].
This non-pathogen associated pro-inflammatory state can
be stimulated and propagated by a variety of damage-
associated molecular patterns (DAMPs) that originate
from damaged tissue and/or tissue under stress [3-5].
Once released, DAMPs bind to pattern-recognition recep-
tors (PRRs) to elicit an immune response by promoting* Correspondence: zobair.younossi@inova.org
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ing the immune cells to the tissue.
Among the five main classes of vertebrate PRRs, the lar-
gest receptor family is comprised by nucleotide oligomeri-
zation and binding domain (NOD)-like receptors (NLRs)
with a conserved NOD motif [6]. NLRs are believed to be
the most evolutionarily ancient family of PRRs [7].
NACHT, LRR and PYD domains-containing proteins
(NLRPs/NALPs) belong to the NOD-like receptor (NLR)
family that differs from other NLRs by their N-terminal
PYD domains [8,9].
Recently NALPs have attracted attention as PRRs that
link recognition of DAMPs with the regulation of in-
flammatory response [7,10]. Human genome encodes 14
NALPs, some of which are required for inflammasome
formation [9]. The inflammasomes are large, signal-induced
multiprotein complexes responsible for the proteolytic
cleavage and activation of procaspases-1. In turn, activated
caspase-1 promotes maturation of the pro-inflammatory
cytokines interleukin-18 (IL-18), interleukin-1β (IL-1β) andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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some is composed of NALP1, apoptosis-associated speck-
like protein containing a carboxy-terminal CARD (ASC),
caspase-1, and caspase-5, whereas the NALP2/3 inflam-
masome contains NALP2 or NALP3, CARDINAL, ASC,
and caspase-1 [13].
The downstream targets of inflammasomes include
known regulators of inflammation and immunity- IL-1β
and IL-18. IL-1β triggers the production of interleukin-6
(IL-6) and tumor necrosis factor-alpha (TNF-α), two cy-
tokines that elicits immune cell migration and infiltra-
tion into tissue [14], and promote the generation and
maintenance of interferon-gamma (IFN-γ) and interleukin-
17 (IL-17) producing T cells [15]. Interleukin-18 (IL-18)
incites immune cell recruitment and activation [11] and
influences natural killer (NK) cell and T cell effector re-
sponses [16,17].
A large number of recent studies have shown adipose
tissue to be the major source of inflammatory molecules
in obesity [18-21]. The expression patterns of NALPs
have not been previously explored in visceral adipose. It
is reasonable to speculate that NALPs may be activated
in adipose tissue of obese individuals and that these
NALPs may contribute to the release of pro-inflammatory
IL-1β and IL-18 from adipocytes, the development of the
systemic inflammation and the obesity-associated progres-
sion of non-alcoholic fatty liver disease (NAFLD) to non-
alcoholic steatohepatitis (NASH).
With this in mind, we profiled visceral adipose expres-
sion of 14 NALPs as well as caspase-1, ASC, IL-18 and
IL-1β in 45 obese subjects (BMI ≥ 35) with biopsy proven
NAFLD. Expression levels of NALPs were correlated to
the serum indicators of system-wide inflammation IL-1β




This study has been approved by Internal Review Board of
Inova Fairfax Hospital. After written informed consent,
omental adipose tissue and serum samples from 45 obese
patients (BMI = 47 ? 11) undergoing bariatric surgery were
collected. The samples were immediately flash frozen in li-
quid nitrogen and added to the repository of specimens
stored at ? 80?C. The samples were de-identified in com-
pliance with HIPAA regulations. For each patient, a liver
biopsy was also performed and subjected to histopatho-
logical evaluation. Clinical data were available for all the
samples in the repository and included pre-surgery fasting
glucose, serum aminotransferases (alanine aminotransfer-
ase (ALT) and aspartate aminotransferase (AST)) and lipid
panel. None of the included subjects reported to have ex-
cessively consumed alcohol (>10 grams/day in women
and >20 grams/day in men) in the past 5 years. Otherchronic liver diseases were excluded by negative serology
for hepatitis B and C, no history of toxic exposure and no
other cause of chronic liver disease.
Pathological assessment
After staining with hematoxylin-eosin or Masson tri-
chrome, the slides were reviewed by single hepatopathol-
ogist (Z.G.) that followed a predetermined histologic
grading system [22] that included quantitative evaluation
of the fibrosis and various inflammatory features.
Definitions and scoring
Steatosis was histologically defined as the presence of >5%
hepatic fat with or without lobular inflammation and
with/without portal inflammation and graded on a scale of
0 ? 3 as follows: 0 = none, 1 ≤ 5%, 2 = 6-33%, 3 = 34-66%,
4 = > 66%. Immune cell infiltrates (lymphoplasmacytic
cells, Kupffer cell hypertrophy and neutrophil presence)
were scored on a score of 0 ? 3 as follows: 0 = none, 1 =
mild or few, 2 =moderate, 3 = marked or many. Lobular
inflammation was defined by sum of scores of the pres-
ence of lymphoplasmacytic cells, Kupffer cell hyper-
trophy and neutrophil infiltration. Portal inflammation,
hepatocellular ballooning, pericellular/perisinusoidal fi-
brosis, and portal fibrosis were graded on a scale of 0 to
3: (0) none, (1) mild or few, (2) moderate, or (3) marked
or many. Advanced fibrosis was defined by a sum of
score of portal and pericellular fibrosis as being greater
or equal to 3. Bridging fibrosis was scored as (0) none,
(1) few bridges, or (2) many bridges. Cirrhosis was scored
as (0) absent, (1) incomplete, or (2) established. NASH was
histologically defined as steatosis, lobular inflammation,
and ballooning degeneration with or without Mallory Denk
bodies, and with or without pericellular fibrosis. Patients
who had hepatic steatosis (with or without lobular inflam-
mation) or NASH were considered to have NAFLD [22].
RNA extraction and reverse transcription
Total RNA was extracted from visceral adipose tissue
(100 mg) using Aurum Total RNA Fatty and Fibrous
Tissue Kit (Bio-Rad, USA) and eluted in 30 uL of RNase
free water (Fisher Scientific, USA). The quantity and
purity of the extracted RNA was determined by absorb-
ance at 260 nm (A260) and 280 nm (A280) measured by
the GeneQuant1300 spectrophotometer (GE Healthcare,
USA). A260/A280 ratio between 1.8 and 2.1 was consid-
ered as an indicator of high quality RNA. The integrity
of total RNA was verified by 1% agarose gel electrophor-
esis with ethidium bromide (10 μg/ml). The results were
documented using Molecular Imager (Bio-Rad, USA).
All total RNA samples demonstrated a 2:1 intensity ratio
of sharp, clear 28S and 18S rRNA bands.
To prevent deterioration of RNA during storage,
cDNA synthesis was carried out on the same day as total
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According to manufacturer ? s protocol, 1 ug of total RNA
was subjected to a genomic DNA elimination step prior
to reverse transcription. Reverse transcription was car-
ried out in the presence of random hexamers and oligo-
dT and resultant cDNA preps were diluted to a final
volume of 111 uL.Table 1 Demographic and clinical characteristics of
patient cohorts profiled for expression of NALPs and
other inflammasome components and targets
Demographic or clinical parameter (N = 45) Average ? SD
or percentage
Clinical & Demographic Data
BMI 47.4 ? 10.8
Age 42.7 ? 11.9
Gender (Females) 62.2%
Triglyceride (mg/dL) 158.3 ? 96.7
AST (U/L) 27.7 ? 18.8
ALT (U/L) 36.7 ? 29.3





Ballooning Degeneration (Presence) 28.8%
Mallory-Denk Bodies (Presence) 11.1%
Portal Inflammation (Presence) 66.6%
Advanced Lobular Inflammation (Score ≥ 3) 28.8%
Pericellular Fibrosis (Presence) 44.4%
Portal Fibrosis (Presence) 75.5%
Advanced Fibrosis (Score ≥ 3) 31.1%Quantitative RT-PCR
Validated primers for specific amplification of NALP1-
NALP14, Caspase-1, ASC, IL-1B and IL-18 mRNA were
as described in relevant publications (see Additional
file 1: Table S1). The specificity of each primer was
verified using NCBI BLAST [23] and the correct size
of PCR product was confirmed by gel electrophoresis
in 2% agarose. For the purpose of normalization, vis-
ceral adipose validated housekeeping gene ACTB was
used as the reference [24].
Quantitative real-time PCR was performed in a 96 well
format in the Bio-Rad CFX96 Real Time System (Bio-
Rad, USA). The real-time PCR mixture consisted of 1 μL
cDNA corresponding to 1 ug of total RNA, 250 nM
primers and 1? Sso Fast Evagreen Supermix (BioRad,
USA) in a final volume of 10 μL. Each plate included no
template control to detect reagent contamination. Each
run also included wells with TATA box binding protein
(TBP) primer pair (Invitrogen, USA) and universal cDNA
(Qiagen, USA) as both an interplate control and a positive
control. The thermal profile of the RT-PCR procedure re-
peated for 50 cycles was: 1) 95?C for 30s; 2) 5 s denatur-
ation at 95?C, 5 s annealing at 60?C (amplification data
collected at the end of each amplification step); 3) dissoci-
ation curve consisting of 10 s incubation at 95?C, 5 s incu-
bation at 65?C, a ramp up to 95?C (Bio-rad CFX96 Real
Time System, USA). Melting curves were used to validate
product specificity. All samples were amplified in tripli-
cates from the same total RNA preparation and the mean
value was used for further analysis. Ct values of target
genes greater than 37 were considered to be a negative call
and assigned a value = 37 for the purpose of normaliza-
tion. Ct values of control wells (no-template control, posi-
tive control) were examined for each plate.Focal Necrosis (Presence) 31.1%
Steatosis is histologically defined by the presence of ≥ 5% hepatic fat with/
without lobular inflammation and with/without portal inflammation. The
degree of lobular inflammation is defined by the sum of the scores for the
presence of lymphoplasmacytic cells, Kupffer cell hypertrophy and neutrophil
infiltration. NASH is histologically defined by the presence of steatosis along
with lobular inflammation, with/without ballooning degeneration and/or
Mallory-Denk bodies and/or pericellular fibrosis. Lymphoplasmacytic cells,
Kupffer cell hypertrophy and neutrophil infiltration was each scored on a scale
of 0 ? 3: 0 = none, 1 =mild or few, 2 =moderate, 3 = marked or many. Portal
inflammation, hepatocellular ballooning, pericellular/perisinusoidal fibrosis, and
portal fibrosis were graded on a scale of 0 to 3: (0) none, (1) mild or few,
(2) moderate, or (3) marked or many. Advanced fibrosis was defined by a sum of
score of portal and pericellular fibrosis as being greater or equal to 3. Bridging
fibrosis was scored as (0) none, (1) few bridges, or (2) many bridges. Cirrhosis was
scored as (0) absent, (1) incomplete, or (2) established [22].ELISA
Serum IL-18 levels were measured by Human IL-18
ELISA kit (R&D systems, USA) according to manufac-
turer ? s instructions. The limits of detection of the assay
were at 12.5 pg/mL. Active serum IL-1β levels were
measured using Quantikine HS Human IL-1β immuno-
assay (R&D systems, USA) according to manufacturer ? s
instructions. The sensitivity ranges from 0.023 pg/mL to
0.14 pg/mL. The limits of detection in this assay was at
0.125 pg/mL.Data analysis
Among samples that differed in their histologically de-
termined severity scores, group comparisons (Table 1)
were performed using non-parametric Mann ? Whitney
U test. Spearman ? s correlation analysis was carried out.
In all cases, the p- values of < 0.05 were considered to be
significant.
Results
NALP4 and IL-1B encoding mRNAs are downregulated in
visceral adipose of patients with pericellular fibrosis
Pericellular fibrosis scores were positively correlated with
both the scores for portal fibrosis (r = 0.5321; p = 0.0003)
and the degree of hepatic steatosis (r = 0.3393; p = 0.03001).
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the levels of NALP4-encoding mRNA were significantly
lower than that in the cohort without the pericellular fi-
brosis (0.18 ? 0.20 vs 1.12 ? 2.53; p < 0.019) (Table 2). The
levels of mRNA for an inflammatory cytokine IL-1B were
also significantly lower in the group with pericellular fibro-
sis (6.17 ? 12.05 vs 14.96 ? 18.21; p < 0.003) (Table 2). Ac-
cordingly, adipose specific expression levels of NALP4 and
IL1B mRNAs negatively correlated with pericellular fibro-
sis (r = ? 0.33; p < 0.037 and r = ? 0.47; p = 0.002, respect-
ively), while circulating levels of IL-18 cytokine were
positively correlated with the scores for this histopatho-
logical feature (r = 0.3365; p < 0.04).NALP6 encoding mRNA and serum levels of IL-18 are
upregulated in portal fibrosis
Expression levels of NALP6 mRNA were significantly
higher in visceral adipose of patients with portal fibrosisTable 2 Significantly altered targets in analyzed cohorts
Pericellular fibrosis presence
AST (U/L) 34.75 ? 25.06
Males 50.0%
Females 35.7%
Advanced fibrosis presence (Score≥ 3) 60%
NALP4 mRNA 0.18 ? 0.20
IL1B mRNA 6.17 ? 12.05
Portal fibrosis presence (N =
Advanced fibrosis presence (Score≥ 3) 45.2%
NASH 58.1%
NALP6 mRNA 0.86 ? 0.93
IL-18 (pg/mL) 390.95 pg/mL ? 176.84
NASH (N = 20)
Gender (Females) 50%
Portal Fibrosis (presence) 1.35 ? 0.67
Pericellular Fibrosis (presence) 1.45 ? 0.60
Advanced fibrosis (Score≥ 3) 60%
Degree of lobular inflammation 2.55 ? 1.61
AST (U/L) 35.70 ? 24.79
NALP 4 mRNA 0.16 ? 0.19
NALP 5 mRNA 0.14 ? 0.12
NALP 7 mRNA 0.14 ? 0.12
NALP 8 mRNA 0.14 ? 0.12
NALP 9 mRNA 0.14 ? 0.12
NALP 10 mRNA 0.14 ? 0.12
NALP 11 mRNA 0.14 ? 0.12
NALP 13 mRNA 0.14 ? 0.12
IL-1B mRNA 8.71 ? 15.45as compared to that of the patients with no evidence of
portal fibrosis (0.86 ? 0.93 vs 0.38 ? 0.38; p = 0.028)
(Table 2). Interestingly, circulating levels of IL-18, an in-
flammatory cytokine that functions downstream of inflam-
masome, were significantly higher in patients with portal
fibrosis (390.95 pg/mL ? 176.84 pg/mL vs 246.08 pg/mL ?
103.10 pg/mL; p = 0.022) (Table 2). Accordingly, circulat-
ing levels of IL-18 were also positively correlated with the
scores for portal fibrosis (r = 0.4226; p < 0.01).Adipose inflammasome signature associated with
inflammatory features and NASH
Among the genes assessed for expression, NALP 4, 5, 7,
8, 9, 10, 11, 13 and IL-1B were significantly downregu-
lated in adipose tissue samples collected from NASH
cohort (Table 2).
CASP-1 mRNA expression levels in adipose were posi-
tively correlated with both the hepatic lobular inflammation(N = 20) Pericellular fibrosis absence (N = 25) P value




1.12 ? 2.53 0.019
14.96 ? 18.21 0.003
34) Portal fibrosis absence (N = 11) P value
0 0.008
20% 0.03
0.38 ? 0.38 0.028
246.08 pg/mL ? 103.10 0.022
Non-NASH NAFLD (N = 25) P value
81% < 0.036
0.71 ? 0.64 < 0.005
0.05 ? 0.22 < 0.001
9.5% < 0.0006
1.52 ? 0.98 < 0.02
21.71 ? 8.52 < 0.004
1.14 ? 2.53 < 0.002
1.24 ? 2.58 < 0.02
1.09 ? 2.54 < 0.03
1.09 ? 2.54 < 0.03
1.25 ? 2.70 < 0.03
1.09 ? 2.54 < 0.03
1.09 ? 2.54 < 0.02
1.09 ? 2.54 < 0.03
12.66 ? 16.68 < 0.02
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determined Kupffer cell hypertrophy (r = 0.41; p = 0.006).
Additionally, expression levels of NALP3 mRNA in adi-
pose were positively correlated with serum levels of liver
enzyme AST (r = 0.32; p = 0.03).
Inflammasome components are co-regulated in adipose
The pattern of the correlation between expression levels
for mRNAs encoding inflammasome components and
its downstream targets (NALP1-14, ASC, CASP-1, IL-1B
and IL-18 mRNA) shows that these genes are co-
regulated in adipose (Table 3). In our study, expression
levels of NALP1 mRNA positively correlated with that
of NALP4 (r = 0.3984; p = 0.01), NALP11 (r = 0.3294; p =
0.04) and NALP14 (r = 0.4134; p = 0.008). Expression
levels of NALP2 mRNAs were positively correlated with
that of all the other non-inflammasome forming NALP
members (NALP4 - NALP14) as well as with levels of
IL-18 mRNA (r = 0.5241, p < 0.001). The expression
levels of NALP3 mRNA were correlated with that of
NALP5 (r = 0.3188, p = 0.04), NALP12 (r = 0.3662, p =
0.02), NALP14 (r = 0.3484, p = 0.027) as well as ASC (r =
0.78, p < 0.001) and CASP-1 (r = 0.389, p = 0.012). The
levels of NALP4 mRNA were co-correlated with levels of
NALP5, NALP7-14 and IL-18 mRNA (Table 3), while
levels of NALP5 mRNA were co-correlated with NALP7-
14 and IL-18 mRNAs (Table 3). NALP6 mRNA levels
were co-correlated with that of NALP12 (r = 0.3227, p =
0.048). The levels mRNAs for NALP7, NALP8, NALP9
and NALP10 were co-correlated with NALP11, NALP12,
NALP14 and IL-18 mRNA (Table 3). The levels of
NALP11 mRNA were co-correlated with NALP12/13/14
and IL-18 mRNA, the levels of NALP12 co-correlated
with NALP13, NALP14, ASC and IL-18 mRNA, and the
levels of NALP13 co-correlated with NALP14 and IL-18
mRNA. The levels of NALP14 were co-correlated with
that of IL-18 mRNA, while the levels of ASC were co-
correlated with that of CASP-1 and IL-1B mRNAs.
Discussion
Systemic inflammation is a common finding in both vis-
ceral obesity and chronic liver disease [25,26]. Inflamma-
some activation has been recently recognized to play an
increasingly important role in the development of liver
disease [27-29]. However, the tissue source and mecha-
nisms of inflammasome mediated liver damage in obesity
associated NAFLD remain disputed [29,30]. Activation of
inflammasomes involves two separate steps, the priming
of tissue to inflammatory response that results in tran-
scriptional activation of NALPs, IL18 and IL1B genes, and
the activation of the inflammasome complex that culmi-
nates in the secretion of active pro-inflammatory IL-1β
and IL-18 cytokines. To better understand the role of adi-
pose specific inflammasome components in NAFLD, weassessed the adipose tissue mRNA for inflammasome
components and serum levels of its downstream targets in
45 morbidly obese patients (BMI ≥ 35) with various liver
conditions of NAFLD spectrum.
Previous studies have shown that the NALP3 inflam-
masome and NALP3-dependent caspase-1 activation are
central to the inflammation and the development of the
liver fibrosis [31]. In our study, expression levels of NALP3
mRNA in adipose were positively correlated with serum
levels of liver enzyme AST(r = 0.32; p = 0.03) and the levels
of mRNA encoding caspase-1 were positively correlated
with Kupffer cell hypertrophy and the hepatic lobular in-
flammation scores. However, to our surprise, the levels of
mRNA encoding for NALP 4, 5, 7, 8, 9, 10, 11, 13 and
IL-1B were significantly downregulated in adipose tissue
samples collected from NASH cohort as compared to
patients without NASH (Table 2). Moreover, the expres-
sion patterns of mRNA for many NALPs, especially for
non-inflammasome forming NALPs, were co-correlated
to each other (Table 3).
So far, only NALPs 1 ? 3 have been shown to form ac-
tive inflammasome, while the functions of other NALPs
remain obscure [9]. Some NALP proteins, for example,
NALP12 and NALP6, have been previously shown to
suppress inflammation through downregulation of NF-κB
signaling subsequent to TLR activation [3]. Another re-
volving theme in the study of non-classic NALPs, for ex-
ample, NALP5, NALP7, NALP8 and NALP9 is their
involvement in oocyte maturation, implantation and other
fertility-related processes [32,33]. It is tempting to specu-
late that the decrease in adipocytic expression of these
NALPs may contribute to decreased fertility in patients
with NASH and metabolic syndrome, possibly through
known association of NASH with polycystic ovary syn-
drome (PCOS) [34,35]. Non-inflammasome related NALPs
may also play as yet unknown roles in pathogenesis of
obesity-associated disorders through modulation of adipo-
cytic secretion or other pathways.
Interestingly, mRNAs encoding for NALP4 and its
substrate IL1B were both downregulated in the cohort
with hepatic pericellular fibrosis, while recently published
study of Boaru et al. showed time and concentration-
dependent increase in expression of NALP4 in cultured
hepatic stellate cells upon lipopolysacharride (LPS) stimu-
lation [29]. This would suggest a role for NALP4 in pro-
moting fibrotic response by activated stellate cells. The
contradiction between our data and observation of Boaru
et al. [29] may be attributed to either yet unknown tissue
specific differences in the function of NALP4, or to a nega-
tive feedback signal operating between adipose tissue and
liver which may be, in fact, time dependent. It is possible
that the inflammation and the fibrotic processes may be
initiated in adipose tissue as described Reggio et al., [36],
but later be shifted to distant organs such as liver. This
Table 3 Correlation among mRNA expression levels of inflammasome components
Rho
(p-value)
NALP1 NALP2 NALP3 NALP4 NALP5 NALP6 NALP7 NALP8 NALP9 NALP10 NALP11 NALP12 NALP13 NALP14 IL18 ASC CASP1 IL1B
NALP1 - - - 0.3984
(0.01)




- - - -
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NALP3 - - - - 0.3188
(0.044)
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originates in the liver and attempts to restore homeostasis.
The observed downregulation of adipose-specific pro-
duction of IL1B mRNA in patients with pericellular fi-
brosis (Table 2 and Figure 1) as well as NASH (Table 2
and Figure 2) also supports this hypothesis. The down-
regulation at expression level is also supported by the
lack of detectable IL1B protein levels in circulation
(Assay Range: 0.125 - 8 pg/mL). Unlike the production
of most inflammatory cytokines, the production of bio-
logically active IL-1β is dependent on transcription,
translation, maturation and secretion mechanisms, all of
which are tightly regulated in tissue-specific manner.
This may be attributed to tissue specific roles of IL1B.
Animal studies showed that hepatic IL-1β protein and
mRNA levels to be increased in various diet-induced
NASH models in mice [28], while adipose specific IL1B
deficiency in mice increase susceptibility to obesity
[28,37]. In another recent study, the authors demon-
strate in animal models that IL-1β supports ectopic fat
accumulation in hepatocytes and adipose-tissue macro-
phages, contributing to impaired fat-liver crosstalk in
nutritional obesity [38]. While the translation of animal
studies to humans is difficult, the discrepancy in ob-
served expression levels of IL1B in obesity associated
NASH and pericellular fibrosis maybe attributed to the
extremely high BMI of the cohort being examined
(BMI ≥ 35). This along with the observed negative correl-
ation of IL1B mRNA levels with BMI (r = ? 0.317; p = 0.04)
indicates an ongoing negative feedback loop between
adipose specific IL1B expression and an accumulation
of VAT.
Further support to the hypothesis centering on on-
going negative feedback loop operating between adipose
tissue and liver in morbidly obese individuals with severe
NAFLD, is provided by result of the comparison inA
Figure 1 Significantly altered gene expression in presence of pericell
expression; B.) IL1B gene expression.another cohort. In cohort of subjects with portal fibrosis
compared to those without portal fibrosis, adipose specific
NALP6 mRNA (Table 2 and Figure 3) and circulating
IL18 (Table 2 and Figure 3) protein were upregulated with
hepatic portal fibrosis, while adipose specific IL18 mRNA
was not significantly different in the same cohort. This is
interesting, since NALP6 has been shown to have an anti-
inflammatory role by downregulating NF-κB signaling
subsequent to TLR activation [3]. Conspicuously, whilst
circulating IL-18 protein was upregulated in portal fibrosis
(Table 2 and Figure 3), this was not accompanied with an
upregulation of adipose specific IL18 mRNA. Additionally,
circulating IL-18 was found to be positively correlated
with BMI (r = 0.41; p = 0.012). This is in agreement with
previous studies [39-43]. Notably, circulating IL-18 levels
are also associated with increased liver injury markers
[44]: AST (r = 0.33; p = 0.04) and ALT (r = 0.41; p = 0.01)
levels respectively as seen in previous reports [43]. Since
IL-18 is more widely expressed, this may indicate add-
itional sources of circulating IL-18 protein such as from
the gut [28] or the liver [45], playing a role in the inflam-
mation and hepatic injury progression. Thus, IL-18 might
contribute to the development of liver disease, albeit the
origin of IL-18 may not be solely from adipose.
For the first time, we profiled gene expression profile
of all the 14 members of NALPs in visceral adipose tis-
sue. As can be seen from correlation analysis (Table 3),
the expression of these genes is significantly correlated
with each other. While most of the studies on obesity
and insulin resistance have focused on NALP3 mediated
inflammasome, our study showed that there is a need
for exploring roles of other members of this family of
proteins in systemic inflammation and chronic liver
conditions.
Among the limitations of this study is that the gene
expression analysis has been carried out in wholeB
ular fibrosis vs absence of pericellular fibrosis. A.) NALP4 gene
Figure 2 Significantly altered gene expression in presence of NASH vs non-NASH NAFLD.
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http://www.biomedcentral.com/1471-230X/14/208adipose tissue instead of studying isolated tissue compo-
nents, i.e. adipocytes and stromal vascular cells. This
study was limited to two markers of systemic inflamma-
tion, IL1B and IL18 that were selected as known targets
released into circulation upon activation. The profiling
of greater variety of inflammatory molecules may yield
better mechanistic resolution of inflammatory responses
in adipose. Another avenue to explore is the parallel
study of NALP component expression in liver and other
peripheral tissues, and the study of NALP components
at protein level.A
Figure 3 Significantly altered targets in presence of portal fibrosis vs ab
IL18 levels.Conclusion
The results of our study indicate that non-inflammasome
related NALPs may play as yet unknown roles in patho-
genesis of obesity-associated disorders through modula-
tion of adipocytic secretion or other pathways. Our
observations also point at a possible shift in inflammation
and fibrotic response from adipose tissue to liver in pa-
tients with severe obesity. While this hypothesis needs
further experimental verification, it takes us a step closer
in understanding the underlying reason for some obese
individuals being metabolically healthy as compared toB
sence of portal fibrosis. A.) NALP6 gene expression; B.) Circulating
Mehta et al. BMC Gastroenterology 2014, 14:208 Page 9 of 10
http://www.biomedcentral.com/1471-230X/14/208metabolically unhealthy obese. Additional study of matched
liver and adipose tissues from same individuals will help
delineate the cross talk mechanisms between inflamma-
tion and fibrosis in obesity and NAFLD.
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